HM2014-26 DT2219 for Relapsed or Refractory B-Lineage Leukemia or Lymphoma

Inclusion Criteria

• •Histologic verification of B-cell lineage leukemia or B cell non-Hodgkin lymphoma and evidence of relapse/refractory disease with the presence of CD19 and/or CD22 by flow cytometry or immunohistochemistry of bone marrow aspirate, peripheral blood or node/tumor biopsy
• •Relapsed refractory disease that has failed conventional therapy and other therapies of higher priority
• •Karnofsky Performance status of ≥ 60% or, if less than 16 years of age, Lansky Play Score of ≥ 60 (appendix II)
• •Recovered from effects of prior therapy
• •Peripheral blast count under 50 x 10\^9/L
• •Adequate organ function within 14 days (30 days for cardiac and pulmonary) of treatment start
• •Women of childbearing potential and men should be advised and agree to practice effective methods of contraception during the course of study
• •Voluntary written consent with appropriate parent/guardian consent and minor information sheet for participants \< 18 years of age